Effects of μ- and δ-opioid-receptor antagonists on the stimulus properties of cholecystokinin

Pharmacology Biochemistry and Behavior

Volumn 57, Issue 1-2, 1997, Pages 57-62

  Riley, Anthony L ^a   Melton, Pamela M ^a  

^a AMERICAN UNIVERSITY   (United States)

Author keywords

; ; CCK; Drug discrimination learning; Naloxone; Naltrindole; Opioid antagonism

Indexed keywords

CHOLECYSTOKININ; DELTA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALOXONE; NALTRINDOLE; SACCHARIN;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN TISSUE; HYPOTHESIS; LEARNING; NONHUMAN; PRIORITY JOURNAL; RAT; STIMULUS RESPONSE;

ANIMALS; CHOLECYSTOKININ; DISCRIMINATION LEARNING; DRUG EVALUATION, PRECLINICAL; FEMALE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STIMULATION, CHEMICAL;

ANIMALIA;

EID: 0030960660     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00119-0     Document Type: Article

References (80)

1. Bansinath, M.; Ramabadran, K.; Turndorf, H.; Puig, M. M. Effects of the benzomorphan κ-opiate, MR 2266 and its (+) enantiomer MR 2267, on thermonociceptive reactions in different strains of mice. Neurosci. Lett. 117:212-217; 1990.
2. Bartolome, J. V.; Lorber, B. A.; Bartolome, M. B. Brain cholecystokinin and B-endorphin systems may antagonistically interact to regulate tissue DNA synthesis in rat pups. Brain Res. 661: 19-24; 1994.
3. Benoliel, J. J.; Bourgoin, S.; Mauborgne, A.; Legrand, J. C.; Hamon, M.; Cesselin, F. Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation. Neurosci. Lett. 124:204-207; 1991.
4. Calcagnetti, D. J.; Calcagnetti, R. L.; Fanselow, M. S. Centrally administered opioid antagonists, nor-binaltorphimine, 16-methyl cyprenorphine and MR2266, suppress intake of sweet solution. Pharmacol. Biochem. Behav. 35:69-73; 1990.
5. Cohen, M. L.; Mendelsohn, L. G.; Mitch, C. H.; Zimmerman, D.M. Use of the mouse deferens to determine μ, δ and K receptor affinities of opioid antagonists. Receptor 4:43-53; 1994.
6. 3H]Naltrindole: A potent and selective ligand for labeling δ-opioid receptors. Brain Res. 604:160-164; 1993.
7. B, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic degradation by systemic RB 101. Pharmacol. Biochem. Behav. 50:133-139; 1995.
8. Derrien, M.; Durieux, C.; Roques, B. P. Antidepressant effects of CCKB antagonists in mice: Antagonism by naltrindole. Br. J. Pharmacol. 111:956-960; 1994.
9. Derrien, M.; Noble, F.; Maldonado, R.; Roques, B. P. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neurosci. Lett. 160:193-196; 1993.
10. Desmeules, J. A.; Kayser, V.; Gacel, G.; Guilbaud, G.; Roques, B. P. The highly selective δ agonist BUBU induces an analgesic effect in normal and arthritic rat and this action is not affected by repeated administration of low doses of morphine. Brain Res. 611:243-248; 1993.
11. B receptors in mediating the inhibitory effect of CCK on opiate analgesia. In: Dourish, C. T.; Cooper, S. J.; Iversen, S. D.; Iversen, L. L., eds. Multiple cholecystokinin receptors in the CNS. Oxford: Oxford University Press; 1992:455-479.
12. Dourish, C. T.; Hawley, D.; Iversen, S. D. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur. J. Pharmacol. 147:469-472; 1988.
13. Dourish, C. T.; O'Neill, M. F.; Coughlan, J.; Kitchener, S. J.; Hawley, D.; Iversen, S. D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 176:35-44; 1990.
14. Dourish, C. T.; O'Neill, M. F.; Schaeffer, L. W.; Siegl, P. K. S.; Iversen, S. D. The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey. J. Pharmacol. Exp. Ther. 255:1158-1165; 1990.
15. Faris, P. L. Opiate antagonistic function of cholecystokinin in analgesia and energy balance systems. Ann. NY Acad. Sci. 448:437-447; 1985.
16. Felicio, L. F.; Mann, P. E.; Bridges, R. S. Intracerebroventricular cholecystokinin infusions block beta-endorphin-induced disruption of maternal behavior. Pharmacol. Biochem. Behav. 39:201-204; 1991.
17. Flood, J. F.; Garland, J. S.; Morley, J. E. Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala. Brain Res. 585:94-104; 1992.
18. Gaudreau, P.; Lavigne, G. J.; Quirion, R. Cholecystokinin antagonists proglumide, lorglumide and benzotript, but not L-364,718, interact with brain opioid binding sites. Neuropeptides 16:51-55; 1990.
19. Han, J.-S.; Ding, X.-Z.; Fan, S.-G. Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous anti-opioid substrates? Neuropeptides 5:399-402; 1985.
20. Hendrie, C. A.; Shepherd, J. K.; Rodgers, R. J. Differential effects of the CCK antagonist, MK-329, on analgesia induced by morphine, social conflict (opioid) and defeat experience (nonopioid) in male mice. Neuropharmacology 28:1025-1032; 1989.
21. B receptor antagonists. Brain Res. 572:208-215; 1992.
22. Hoffmann, O.; Wiesenfeld-Hallin, Z. The CCK-B receptor antagonist CI 988 reverses tolerance to morphine in rats. Neuroreport 5:2565-2568; 1994.
23. Hong, E. K.; Takemori, A. E. Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice. J. Pharmacol. Exp. Ther. 251:594-598; 1989.
24. Itoh, S.; Katsuura, G. Effects of B-endorphin, thyrotropin-releasing hormone and cholecystokinin on body shaking behavior in rats. Jpn. J. Physiol. 32:667-675; 1982.
25. Jarbe, T. U. C. Discrimination learning with drug stimuli:Methods and applications. In: Boulton, A. A.; Baker, G. B.; Greenshaw, A. J., eds. Neuromethods, vol. 13: Psychopharmacology. Clifton, NJ: Humana Press; 1989:513-563.
26. Kapas, L.; Benedek, G.; Penke, B. Cholecystokinin interferes with the thermoregulatory effects of exogenous and endogenous opioids. Neuropeptides 14:85-92; 1989.
27. Laorden, M. L.; Carrillo, E.; Puig, M. M. Prevention of hyperthermia-induced convulsions in immature rat by MR-2266, a kappa antagonist. Methods Find. Exp. Clin. Pharmacol. 13:605-608; 1991.
28. Lavigne, G. J.; Millington, W. R.; Mueller, G. P. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in nonacclimated rats exposed to a novel environment. Neuropeptides 21:119-129; 1992.
29. 11C]methyl) naltrindole to δ-opioid receptors in mouse brain. Eur. J. Pharmacol. 216:459-460; 1992.
30. Lord, J. A. H.; Waterfield, A. A.; Hughes, J.; Kosterlitz, H. W. Endogenous opioid peptides: Multiple agonists and receptors. Nature 267:495-499; 1977.
31. Lucki, I. Rapid discrimination of the stimulus properties of 5-hydroxytryptamine agonist using conditioned taste aversion. J. Pharmacol. Exp. Ther. 247:1120-1127; 1988.
32. Magnan, J.; Paterson, S. J.; Tavani, A.; Kosterlitz, H. W. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmied. Arch. Pharmacol. 319:197-205; 1982.
33. Martin, G. M.; Gans, M.; van der Kooy, D. Discriminative properties of morphine that modulate associations between tastes and lithium chloride. J. Exp. Psychol. Anim. Behav. Proc. 16:56-68; 1990.
34. Martin, W. R. Opioid antagonists. Pharmacol. Rev. 19:463-521; 1967.
35. Mastropaolo, J. P.; Moskowitz, K. H.; Dacanay, R. J.; Riley, A. L. Conditioned taste aversions as a behavioral baseline for drug discrimination learning: An assessment with phencyclidine. Pharmacol. Biochem. Behav. 32:1-8; 1989.
36. Melton, P. M.; Kopman, J. A.; Riley, A. L. Cholecystokinin as a stimulus in drug discrimination learning. Pharmacol. Biochem. Behav. 44:249-252; 1993.
37. Melton, P. M.; Riley, A. L. An assessment of the interaction between cholecystokinin and the opiates within a drug discrimina-tion procedure. Pharmacol. Biochem. Behav. 46:237-242; 1993.
38. Melton, P. M.; Riley, A. L. Receptor mediation of the stimulus properties of cholecystokinin. Pharmacol. Biochem. Behav. 48:275-279; 1994.
39. Menkens, K.; Bilsky, E. J.; Wild, K. D.; Portoghese, P. S.; Reid, L. D.; Porreca, F. Cocaine place preference is blocked by δ-opioid receptor antagonist, naltrindole. Eur. J. Pharmacol. 219:345-346; 1992.
40. Micevych, P. E.; Go, V. L. W.; Yaksh, T. L.; Finkelstein, J. In vitro release of cholecystokinin from hypothalamus and frontal cortex of Sprague-Dawley, Zucker lean (Fa/-) and obese (fa/fa) rats. Peptides 5:73-80; 1984.
41. Micevych, P. E.; Yaksh, T. L.; Go, V. L. W. Opiate-mediated inhibition of the release of cholecystokinin and substance P but not neurotensin from cat hypothalamic slices. Brain Res. 250:283-289; 1982.
42. +-stimulated cholecystokinin and substance P released from cat hypothalamus, in vitro. Brain Res. 290:87-94; 1983.
43. Micevych, P. E.; Yaksh, T. L.; Go, V. L. W.; Finkelstein, J. A. Effect of opiates on the release of cholecystokinin from in vitro hypothalamus and frontal cortex of Zucker lean (Fa/-) and obese (fa/fa) rats. Brain Res. 337:382-385; 1985.
44. Miller, K. K.; Lupica, C. R. Morphine-induced excitation of pyramidal neurons is inhibited by cholecystokinin in the CA1 region of the rat hippocampal slice. J. Pharmacol. Exp. Ther. 268:753-761; 1994.
45. 3H]TIPP. Life Sci. 53:57-62; 1993.
46. Ohno, M.; Yamamoto, T.; Ueki, S. Effect of the κ-receptor agonist, U50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task. Eur. J. Pharmacol. 193:357-361; 1991.
47. O'Neill, M. F.; Dourish, C. T.; Iversen, S. D. Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329. Neuropharmacology 28:243-247; 1989.
48. O'Neill, M. F.; Dourish, C. T.; Tye, S. J.; Iversen, S.D. Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey. Brain Res. 534:287-290; 1990.
49. B antagonist in the rat. Neurosci. Lett. 181:9-12; 1994.
50. Overton, D. A. Applications and limitations of the drug discrimination method for the study of drug abuse. In: Bozarth, M. A., ed. Methods of assessing the reinforcing properties of abused drugs. Berlin: Springer-Verlag; 1987:291-340.
51. Pournaghash, S.; Riley, A. L. Buprenorphine as a stimulus in drug discrimination learning: An assessment of mu and kappa receptor activity. Pharmacol. Biochem. Behav. 46:593-604; 1993.
52. Pournaghash, S.; Riley, A. L. Failure of cholecystokinin to precipitate withdrawal in morphine-treated rats. Pharmacol. Biochem. Behav. 38:479-484; 1991.
53. B receptors in regula-tion of ion transport. J. Pharmacol. Exp. Ther. 268:1003-1009; 1994.
54. Reid, L. D.; Hubbell, C. L.; Glaccum, M. B.; Bilsky, E. J.; Portoghese, P. S.; Porreca, F. Naltrindole, an opioid delta receptor antagonist, blocks cocaine-induced facilitation of responding for rewarding brain stimulation. Life Sci. 52:67-71; 1993.
55. Rezayat, M.; Nikfar, S.; Zarrindast, M.-R. CCK receptor activation may prevent tolerance to morphine in mice. Eur. J. Pharmacol. 254:21-26; 1994.
56. Richards, M. L.; Sadee, W. Buprenorphine is an antagonist at the K opioid receptor. Pharm. Res. 2:178-181; 1985.
57. Riley, A. L. Use of drug discrimination learning in behavioral toxicology: Classification and characterization of toxins. In: Chang, L.; Slikker, W., eds. Neurotoxicology: Approaches and methods. New York: Academic Press; 1995:309-321.
58. Riley, A. L.; Kautz, M. A.; Geter, B.; Smurthwaite, S. T.; Pournaghash, S.; Melton, P. M.; Ferrari, C. M. A demonstration of the graded nature of the generalization function of drug discrimination learning within the conditioned taste aversion procedure. Behav. Pharmacol. 2:323-334; 1991.
59. Riley, A. L.; Pournaghash, S. The effects of chronic morphine on the generalization of buprenorphine stimulus control: An assessment of kappa antagonist activity. Pharmacol. Biochem. Behav. 52:779-787; 1996.
60. Rogers, H.; Hayes, A. G.; Birch, P. J.; Traynor, J. R.; Lawrence, A. J. The selectivity of the opioid antagonist, naltrindole, for δ-opioid receptors. J. Pharm. Pharmacol. 42:358-359; 1990.
61. Samele, C.; Shine, P. J.; Stolerman, I. P. Forty years of drug discrimination research: A bibliography for 1951-1991. NIDA administrative document, National Clearinghouse for Alcohol and Drug Information, 1992.
62. Schnur, P.; Cesar, S. S.; Foderaro, M. A.; Kulkosky, P. J. Effects of cholecystokinin on morphine-elicited hyperactivity in hamsters. Pharmacol. Biochem. Behav. 39:581-586; 1991.
63. Schnur, P.; Raigoza, V. P.; Sanchez, M. R.; Kulkosky, P. J. Cholecystokinin antagonizes morphine induced hypoactivity and hyperactivity in hamsters. Pharmacol. Biochem. Behav. 25:1067-1070; 1986.
64. Slaninova, J.; Knapp, R. J.; Wu, J.; Fang, S.-N.; Kramer, T.;Burks, T. F.; Hruby, V. J.; Yamamura, H. I. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide. Eur. J. Pharmacol. 200:195-198; 1991.
65. Sofuoglu, M.; Portoghese, P. S.; Takemori, A. E. Differential antagonism of delta opioid agonists bynaltrindole and its benzofuran analog (NTB) in mice: Evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257:676-680; 1991.
66. Stolerman, I. P. Measures of stimulus generalization in drug discrimination experiments. Behav. Pharmacol. 2:265-282; 1991.
67. Suzuki, T.; Mori, T.; Funada, M.; Misawa, M.; Nagase, H. Attenuation of the discriminative stimulus properties of cocaine by δ-opioid receptor antagonists. Eur. J. Pharmacol. 263:207-211; 1994.
68. Suzuki, T.; Mori, T.; Tsuji, M.; Misawa, M.; Nagase, H. The role of δ-opioid receptor subtypes in cocaine- and methamphetamine-induced place preferences. Life Sci. 55:339-344; 1994.
69. Suzuki, T.; Yoshiike, M.; Mizoguchi, H.; Kamei, J.; Misawa, M.; Nagase, H. Blockade of δ-opioid receptors prevents morphine-induced place preferences in mice. Jpn. J. Pharmacol. 66:131-137; 1994.
70. Wang, X.-J.; Han, J.-S. Modification by cholecystokinin octapeptide of the binding of μ-, δ- and κ-opioid receptors. J. Neurochem. 55:1379-1382; 1990.
71. Wang, X.-J.; Wang, X.-H.; Han, J.-S. Cholecystokinin-octapeptide antagonized opioid analgesia mediated by μ- and κ- but not δ-receptors in the spinal cord of the rat. Brain Res. 523:5-10; 1990.
72. Watkins, L. R.; Kinscheck, I. B.; Kaufman, E. F. S.; Miller, J.; Frenk, H.; Mayer, D. J. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res. 327:181-190; 1985.
73. Watkins, L. R.; Kinscheck, I. B.; Mayer, D. J. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res. 327:169-180; 1985.
74. Wiesenfeld-Hallin, Z.; Xu, X.-J.; Hughes, J.;Horwell, D. C.; Hokfelt, T. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Natl. Acad. Sci. USA 87:7105-7109; 1990.
75. Wilson, M. C.; Denson, D.; Bedford, J. A.; Hunsinger, R. N. Pharmacological manipulation of sincalide (CCK8)-induced suppression of feeding. Peptides 4:351-357; 1983.
76. Wollemann, M.; Benyhe, S.; Simon, J. The kappa-opioid receptor: Evidence for the different subtypes. Life Sci. 52:599-611; 1993.
77. Wood, P. L. Multiple opiate receptors: Support for unique mu, delta and kappa sites. Neuropharmacology 21:487-497; 1982.
78. Xu, X.-J.; Hokfelt, T.; Hughes, J.; Wiesenfeld-Hallin, Z. The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats. Neuroreport 5:718-720; 1994.
79. B receptors, prevents morphine tolerance in the rat. Br. J. Pharmacol. 105:591-596; 1992.
80. Zimmerman, D. M.; Leander, J. D. Selective opioid receptor agonists and antagonists: Research tools and potential therapeutic agents. J. Med. Chem. 33:895-902; 1990.